Zhong Guo Xin Wen Wang·2025-08-01 11:02Core Viewpoint - On the first trading day of August, China's A-shares experienced a correction with major indices declining, but the traditional Chinese medicine sector showed resilience, rising significantly [1] Market Performance - The traditional Chinese medicine sector increased by 3.39%, leading all industry sectors in A-shares [1] - Notable individual stocks included Weikang Pharmaceutical, Tianmu Pharmaceutical, Xintian Pharmaceutical, and Huason Pharmaceutical, with Weikang Pharmaceutical achieving approximately a 20% increase [1] - The Shanghai Composite Index closed at 3559 points, down 0.37%; the Shenzhen Component Index closed at 10991 points, down 0.17%; and the ChiNext Index closed at 2322 points, down 0.24% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 15,984 billion RMB, a decrease of about 3,377 billion RMB compared to the previous trading day [1] Industry Developments - The Long Triangle Traditional Chinese Medicine Concept Verification and Achievement Transformation Center was officially launched, aiming to address early bottlenecks in the transformation of traditional Chinese medicine achievements [1] Analyst Insights - According to Guo Yiming, Director of Investment Advisory at Jifeng Investment Consulting, the decline in A-shares on August 1 was primarily a technical adjustment due to the indices reaching a phase high, coupled with profit-taking [1] - The overall outlook remains positive, with the fundamental recovery of the Chinese economy, improved market liquidity, and supportive policies indicating limited downward space for the indices in the future [1]